Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV - 12/03/25
, Delphine Sauce b, Randa Bittar c, d, José Fernandez a, Henri Thévenet a, Elisa Teyssou a, Rana Alkouri c, Dominique Bonnefont-Rousselot c, e, Anne-Geneviève Marcelin a, Vincent Calvez a, Valérie Pourcher f, gGraphical abstract |
Highlights |
• | SGLT2i use was associated with a median weight loss of 3 kg in people living with HIV (PWH). |
• | SGLT2i use in PWH was linked to significant changes in surrogate markers associated with their clinical impact. |
• | SGLT2i may decrease IL-1 β and IL-8 levels, consistent with inflammasome inhibition. |
• | SGLT2i may inhibit both monocyte-macrophage-associated cytokines and their feedback. |
Abstract |
Introduction |
Positive cardiovascular and renal outcomes associated with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) use are attributed to their anti-inflammatory properties. Persistent immune activation accounts for part of the elevated cardiovascular risk of people living with HIV (PWH), but SGLT2i impact on this population has been poorly described.
Methods |
All PWH with a history of SGLT2i treatment from May 2020 to April 2023 receiving care at Pitié-Salpêtrière Hospital (Paris, France) and with available pre- and post-treatment blood samples were included. Clinical and biological data were extracted from medical records, metabolic and immune biomarkers from cryopreserved plasma samples.
Results |
Most of the 20 patients with SGLT2i treatment were men (75 %), with a median [IQR] age of 59 years [55;68], receiving antiretroviral therapy for a median of 21.5 years [15.3;26.5]. Most had type 2 diabetes (95 %), chronic kidney disease (90 %), dyslipidemia (80 %), and hypertension (75 %). SGLT2i treatment was associated with a median weight loss of 3 kg, an increase in hematocrit, and decreased AST levels. LDL, HDL, oxLDL, and Lp-PLA2 levels were unaffected. SGLT2i was associated with inflammasome inhibition and with decreased circulating levels of IL-1β and IL-8. We also observed a decrease in cytokines associated with the recruitment and activation of monocytes-macrophages MCP-1, MIP-1α, MIP-1β, Eotaxin, RANTES, IL-8, and their positive feedback, IL-13/IL-4. Decreased IL-6, CRP, and sCD14 levels were not significant.
Conclusion |
SGLT2i was associated with weight loss and a significant impact on innate immunity in PWH, with inhibition of inflammasome and monocyte-macrophage activation.
Le texte complet de cet article est disponible en PDF.Keywords : Dapagliflozin, Empagliflozin, HIV, SGLT2, Metabolism
Plan
Vol 55 - N° 2
Article 105040- mars 2025 Retour au numéro
Article précédent
- Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE
- Lionel Piroth, Virginie Vitrat, Vincent Le Moing, Philippe Bret, Yves Brault, William Greenwood, Marie-Charlotte Chopin, Eric Vicaut, Philippe Montravers, Pierre Tattevin, Alexandre Bleibtreu, on behalf of the OZAVIE research group
- Low-level primary clarithromycin resistance of Helicobacter pylori in Reunion Island
- Arthur Charazac, Raphael Delage, Maxime Pichon, Laure Kamus, Benoit Pichard, Laura Peyret-Moreau, Olivier Belmonte, Guillaume Miltgen, Christophe Burucoa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?